Avinger Inc. (NASDAQ:AVGR) was down 3.5% during mid-day trading on Wednesday . The stock traded as low as $4.00 and last traded at $4.09, with a volume of 107,912 shares traded. The stock had previously closed at $4.24.

Several equities research analysts have recently issued reports on AVGR shares. Zacks Investment Research raised shares of Avinger from a “sell” rating to a “hold” rating in a research report on Tuesday, May 3rd. Canaccord Genuity reissued a “buy” rating on shares of Avinger in a research report on Tuesday, July 12th. Finally, BTIG Research reissued a “buy” rating and issued a $18.00 price target on shares of Avinger in a research report on Friday, July 15th. Two research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The company presently has an average rating of “Buy” and a consensus price target of $15.75.

The firm’s 50 day moving average price is $5.10 and its 200 day moving average price is $10.07. The company’s market capitalization is $52.40 million.

Avinger (NASDAQ:AVGR) last released its quarterly earnings data on Monday, August 1st. The medical device company reported ($1.06) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.15) by $0.09. The business earned $4.70 million during the quarter, compared to analyst estimates of $3.05 million. Equities analysts predict that Avinger Inc. will post ($4.16) EPS for the current year.

In other Avinger news, CEO Jeffrey M. Soinski acquired 57,100 shares of the company’s stock in a transaction dated Tuesday, August 16th. The stock was bought at an average price of $3.50 per share, with a total value of $199,850.00. Following the completion of the transaction, the chief executive officer now directly owns 59,345 shares of the company’s stock, valued at $207,707.50. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Avinger, Inc is a commercial-stage medical device company. The Company designs, manufactures and sells image-guided, catheter-based systems that are used by physicians to treat patients with peripheral arterial disease (PAD). The Company focuses on introducing products based on its lumivascular platform, which is an intravascular image-guided system.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.